We are concerned that some of the coverage of this story has been over-hyped and misleading.

She added:

It’s important to be cautious about the results from the early-stage trial of ImMucin reported in the media, which are based on data from seven patients (out of ten treated so far) with multiple myeloma – a cancer affecting the immune system.

Furthermore, the team’s results are yet to be published in the scientific literature – the ‘gold standard’ for reliable research. Instead, the results have come directly from a press release from Vaxil Biotherapeutics Ltd, the company that makes the vaccine – something that wasn’t made clear in some of the media coverage of the story...

While MUC1 is certainly an important target in cancer and the results from the handful of myeloma patients in the ImMucin trial look promising, it’s a far cry from being a “wonder jab” that “kills 90% of all cancers”.

Finally, Arney noted that following the publication of these stories, Cancer Research UK had been contacted by concerned patients asking about the treatment:

We’ve already been contacted by cancer patients wondering how to get access to this “wonder jab” as a result of the news coverage. As we’ve said before, over-hyped stories like this only serve to raise false hopes in people suffering from cancer and mislead the public.

Every day cancer researchers in labs and hospitals around the world are making huge strides against this terrible disease, and their progress and successes deserve to be reported to the public. But misrepresenting and over-selling their early baby-steps isn’t helpful to anyone, most of all cancer patients and their families.

Perhaps Cancer Research UK should forward these calls to the Telegraph's Richard Gray and the Express' Paul Broster.